Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tylerdipine Hydrochloride - Sihuan Pharmaceutical Holdings Group

Drug Profile

Tylerdipine Hydrochloride - Sihuan Pharmaceutical Holdings Group

Alternative Names: 5660; KBP 5660

Latest Information Update: 28 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group
  • Developer Nanjing Medical University; Sihuan Pharmaceutical Holdings Group
  • Class Antihypertensives; Small molecules
  • Mechanism of Action L-type calcium channel agonists; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertension

Most Recent Events

  • 27 Oct 2018 Phase I development is ongoing in China
  • 27 Oct 2018 Safety and pharmacokinetics data from two phase I trials in healthy volunteers released by the Nanjing Medical University
  • 27 Oct 2018 Nanjing Medical University completes two phase I trials in healthy volunteers in China before October 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top